PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
NEW YORK, May 28, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p01190422/PharmaPoint-Chronic-Myeloid-Leukemia-CML---United-Kingdom-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
Summary
GlobalData has released its new Country report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022". Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients' survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems
The UK has the second lowest prevalence of CML, and is currently the smallest CML market of the 7MM. Although an increasing prevalence of CML and the launch of Bosulif and Iclusig will act as driving forces of market growth, it will not be enough to compensate for erosion of Gleevec and Sprycel sales once their generic equivalents hit the market.
Scope
- Overview of the CML including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK CML market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for CML
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the UK
Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Clinical Staging 14
3.1.4 Prognosis 15
3.1.5 Quality of Life 16
3.2 Symptoms 16
4 Disease Management 18
4.1 Global Trends 18
4.1.1 Treatment Overview 18
4.1.2 Diagnostic Tests 20
4.1.3 Genetic Testing 21
4.1.4 Monitoring Patient Response to Treatment 23
4.1.5 Future Directions: Discontinuation Therapy 26
4.2 UK 27
4.2.1 Diagnosis and Monitoring 27
4.2.2 Clinical Treatment 27
4.2.3 Genetic Testing 29
5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 30
5.3 Product Profiles- Major Brands 33
5.3.1 Gleevec (imatinib) 33
5.3.2 Sprycel (dasatinib) 37
5.3.3 Tasigna (nilotinib) 43
5.3.4 Bosulif (bosutinib) 48
5.3.5 Iclusig (ponatinib) 53
5.3.6 Minor Therapeutic Classes 57
6 Opportunity and Unmet Need 59
6.1 Overview 59
6.2 Unmet Need: A Drug that Can Cure CML 60
6.3 Unmet Need: Lower Annual Cost of Therapy 61
6.4 Unmet Need: Treatments for Patients Who Have Primary Resistance to or are Refractory to TKIs 62
6.5 Unmet Need: More Efficacious Treatments for AP and BP CML 62
6.6 Unmet Need: Therapies with Fewer Chronic Side Effects 63
6.7 Unmet Need: Better Compliance from Patients on Long-Term Oral Therapy 63
6.8 Unmet Need: Methods of Determining the Optimal Therapy for a Patient 64
6.9 Opportunity: Exploration into Discontinuation Therapy 64
6.10 Opportunity: Companion Devices to Enhance Patient Adherence to Oral Therapy 65
6.11 Opportunity: Therapies with BCR-ABL Independent MOAs 65
6.12 Opportunity: Extended-Release Formulations of TKIs 66
6.13 Opportunity: Biomarkers to Identify the Optimal Therapy for a Given Patient 66
7 Pipeline Assessment 67
7.1 Overview 67
7.2 Innovative Early-Stage Approaches 67
7.2.1 Project 1: The Wnt Signaling Pathway 69
7.2.2 Project 2: Jak2 Inhibitors 70
7.2.3 Project 3: Grb-2 71
7.2.4 Case Study: Smoothened Inhibitors 72
8 Market Outlook 73
8.1 UK 73
8.1.1 Forecast 75
8.1.2 Key Events 76
8.1.3 Drivers and Barriers 76
9 Appendix 79
9.1 Bibliography 79
9.2 Abbreviations 85
9.3 Methodology 88
9.4 Forecasting Methodology 88
9.4.1 Diagnosed CML patients 88
9.4.2 Drug-treated Patients on X Line of Therapy 89
9.4.3 Drugs Included in Each Therapeutic Class 89
9.4.4 Launch and Patent Expiry Dates 89
9.4.5 General Pricing Assumptions 90
9.4.6 Compliance Assumptions for Oral TKIs 90
9.4.7 Individual Drug Assumptions 91
9.4.8 Generic Erosion 93
9.4.9 Pricing of New Market Entrants 93
9.5 Physicians and Specialists Included in this Study 94
9.6 Survey of High Prescribing Physicians 95
9.7 About the Authors 96
9.7.1 Authors 96
9.7.2 Epidemiologists 97
9.7.3 Global Director of Epidemiology and Clinical Trials Analysis 98
9.7.4 Global Head of Healthcare 99
9.8 About GlobalData 100
9.9 Contact Us 100
9.10 Disclaimer 100
List of Tables
Table 1: The Staging of CML as Defined by Commonly Used Staging Systems 14
Table 2: Prognostic Scoring Systems for CML 15
Table 3: Common Symptoms of CML by Disease Phase 17
Table 4: Most Commonly Followed Treatment Guidelines for CML 19
Table 5: Most Prescribed First-Line Therapies for CP, AP and BP CML in the Global Markets, 2013 20
Table 6: Suggested Treatments for CML Patients with Selected BCR-ABL Kinase Domain Mutations 23
Table 7: CML Response Types, Criteria, and Corresponding Tests 24
Table 8: Leading Treatments for Chronic Myeloid Leukemia, 2013 32
Table 9: Product Profile – Gleevec 34
Table 10: Hematologic and Cytogenetic Reponses to Gleevec in Newly Diagnosed CML Patients 35
Table 11: Gleevec SWOT Analysis, 2013 37
Table 12: Product Profile – Sprycel 39
Table 13: Hematologic and Cytogenetic Reponses to Sprycel in Imatinib Resistant or Intolerant Advanced Phase CML 40
Table 14: Sprycel SWOT Analysis, 2013 42
Table 15: Product Profile – Tasigna 44
Table 16: Molecular and Cytogenetic Responses of Tasigna Compared with Gleevec in Newly Diagnosed Ph+ CML in CP 45
Table 17: Tasigna SWOT Analysis, 2013 47
Table 18: Product Profile – Bosulif 49
Table 19: Bosulif SWOT Analysis, 2013 52
Table 20: Product Profile – Iclusig 54
Table 21: Iclusig SWOT Analysis, 2013 57
Table 22: Summary of Minor Therapeutic Classes, 2013 58
Table 23: Overall Unmet Needs – Current Level of Attainment 60
Table 24: Early-stage Pipeline Projects in CML 68
Table 25: Sales Forecasts ($m) for CML Therapeutics in the United Kingdom, 2012–2022 75
Table 26: Key Events Impacting Sales of CML Therapeutics in the UK, 2013 76
Table 27: CML Market in the UK – Drivers and Barriers, 2013 76
Table 28: Key Launch Dates 89
Table 29: Key Patent Expiries 89
Table 30: Physicians Surveyed, by Country 95
List of Figures
Figure 1: Translocation of Chromosomes 9 and 22 12
Figure 2: Comparison of Normal and Leukemia Blood Cells 13
Figure 3: Sales for CML Therapeutics in the UK by Brand, 2012–2022 75
To order this report:
Pathology Industry: PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article